Eaton Corporation R&D increased by 3.9% to $211.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.6%, from $198.00M to $211.00M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 6.6% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $154.00M | $152.00M | $162.00M | $165.00M | $168.00M | $165.00M | $167.00M | $179.00M | $187.00M | $187.00M | $201.00M | $189.00M | $196.00M | $207.00M | $201.00M | $198.00M | $192.00M | $203.00M | $203.00M | $211.00M |
| QoQ Change | — | -1.3% | +6.6% | +1.9% | +1.8% | -1.8% | +1.2% | +7.2% | +4.5% | +0.0% | +7.5% | -6.0% | +3.7% | +5.6% | -2.9% | -1.5% | -3.0% | +5.7% | +0.0% | +3.9% |
| YoY Change | — | — | — | — | +9.1% | +8.6% | +3.1% | +8.5% | +11.3% | +13.3% | +20.4% | +5.6% | +4.8% | +10.7% | +0.0% | +4.8% | -2.0% | -1.9% | +1.0% | +6.6% |